Format

Send to

Choose Destination
J Ayurveda Integr Med. 2018 Jan - Mar;9(1):45-52. doi: 10.1016/j.jaim.2017.07.004. Epub 2017 Dec 15.

Anti-hyperglycemic and anti-hyperlipidaemic effect of Arjunarishta in high-fat fed animals.

Author information

1
Dr. Prabhakar Kore Basic Science Research Centre, KLE Academy of Higher Education and Research (KLE University), Belagavi, Karnataka, India.
2
Department of Biotechnology, Sinhgad College of Engineering, Vadgoan (Bk), Pune, India. Electronic address: joshikalpana@gmail.com.
3
APT Research Foundation, Vadgoan Khurd, Pune, India.
4
Serum Institute of India Research Foundation, Hadapsar, Pune, India.
5
Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.

Abstract

BACKGROUND:

Arjunarishta (AA), a formulation used as cardiotonic is a hydroalcoholic formulation of Terminalia arjuna (Roxb.) Wight and Arn. (TA) belonging to family Combretaceae.

OBJECTIVE:

To evaluate the anti-hyperglycemic and anti-hyperlipidemic effect of Arjunarishta on high-fat diet fed animals.

MATERIALS AND METHODS:

High-fat diet fed (HFD) Wistar rats were randomly divided into three groups and treated with phytochemically standardized Arjunarishta (1.8 ml/kg), and hydroalcoholic extract of T. arjuna (TAHA) (250 mg/kg) and rosuvastatin (10 mg/kg), for 3 months. Intraperitoneal glucose tolerance test, blood biochemistry, liver triglyceride and systolic blood pressure were performed in all the groups. Effect of these drugs on the expression of tumor necrosis factor-α (TNF-α) and insulin receptor substrate-1 (IRS-1) and peroxisome proliferators activated receptor γ coactivator 1-α (PGC-1α) were studied in liver tissue using Quantitative Real-time PCR.

RESULTS:

HFD increased fasting blood glucose, liver triglyceride, systolic blood pressure and gene expression of TNF-α, IRS-1 and PGC-1α. Treatment of AA and TAHA significantly reduced fasting blood glucose, systolic blood pressure, total cholesterol and triglyceride levels. These treatments significantly decreased gene expression of TNF-α (2.4, 2.2 and 2.6 fold change); increased IRS-1 (2.8, 2.9 and 2.8 fold change) and PGC-1α (2.9, 3.7 and 3.3 fold change) as compared to untreated HFD.

CONCLUSION:

Anti-hyperglycemic, anti-hyperlipidemic effect of Arjunarishta may be mediated by decreased TNF-α and increased PGC-1α and IRS-1.

KEYWORDS:

Arjunarishta; Insulin sensitizer genes; Rosuvastatin; Type 2 diabetes

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center